142 related articles for article (PubMed ID: 27783972)
1. Discovery of oral-available resveratrol-caffeic acid based hybrids inhibiting acetylated and phosphorylated STAT3 protein.
Li S; Zhang W; Yang Y; Ma T; Guo J; Wang S; Yu W; Kong L
Eur J Med Chem; 2016 Nov; 124():1006-1018. PubMed ID: 27783972
[TBL] [Abstract][Full Text] [Related]
2. Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy.
Zhang W; Guo J; Li S; Ma T; Xu D; Han C; Liu F; Yu W; Kong L
Sci Rep; 2017 Apr; 7():46352. PubMed ID: 28397855
[TBL] [Abstract][Full Text] [Related]
3. Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules.
Zhang W; Ma T; Li S; Yang Y; Guo J; Yu W; Kong L
Eur J Med Chem; 2017 Jan; 125():538-550. PubMed ID: 27718470
[TBL] [Abstract][Full Text] [Related]
4. Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors.
Gao D; Jin N; Fu Y; Zhu Y; Wang Y; Wang T; Chen Y; Zhang M; Xiao Q; Huang M; Li Y
Eur J Med Chem; 2021 Apr; 216():113333. PubMed ID: 33689932
[TBL] [Abstract][Full Text] [Related]
5. Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors.
Cai G; Yu W; Song D; Zhang W; Guo J; Zhu J; Ren Y; Kong L
Eur J Med Chem; 2019 Jul; 174():236-251. PubMed ID: 31048139
[TBL] [Abstract][Full Text] [Related]
6. A Resveratrol Analogue Promotes ERKMAPK-Dependent Stat3 Serine and Tyrosine Phosphorylation Alterations and Antitumor Effects In Vitro against Human Tumor Cells.
Chelsky ZL; Yue P; Kondratyuk TP; Paladino D; Pezzuto JM; Cushman M; Turkson J
Mol Pharmacol; 2015 Sep; 88(3):524-33. PubMed ID: 26138072
[TBL] [Abstract][Full Text] [Related]
7. Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling.
Zhu F; Dai C; Fu Y; Loo JF; Xia D; Gao SP; Ma Z; Chen Z
Oncotarget; 2016 Feb; 7(8):9462-76. PubMed ID: 26843613
[TBL] [Abstract][Full Text] [Related]
8. Identification of New Shikonin Derivatives as Antitumor Agents Targeting STAT3 SH2 Domain.
Qiu HY; Zhu X; Luo YL; Lin HY; Tang CY; Qi JL; Pang YJ; Yang RW; Lu GH; Wang XM; Yang YH
Sci Rep; 2017 Jun; 7(1):2863. PubMed ID: 28588262
[TBL] [Abstract][Full Text] [Related]
9. Pterostilbene exerts antitumor activity against human osteosarcoma cells by inhibiting the JAK2/STAT3 signaling pathway.
Liu Y; Wang L; Wu Y; Lv C; Li X; Cao X; Yang M; Feng D; Luo Z
Toxicology; 2013 Feb; 304():120-31. PubMed ID: 23313376
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of STAT3 signaling as critical molecular event in resveratrol-suppressed ovarian cancer cells.
Zhong LX; Li H; Wu ML; Liu XY; Zhong MJ; Chen XY; Liu J; Zhang Y
J Ovarian Res; 2015 Apr; 8():25. PubMed ID: 25896424
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of a novel oral signal transducer and activator of transcription 3 inhibitor YHO-1701.
Nishisaka F; Taniguchi K; Tsugane M; Hirata G; Takagi A; Asakawa N; Kurita A; Takahashi H; Ogo N; Shishido Y; Asai A
Cancer Sci; 2020 May; 111(5):1774-1784. PubMed ID: 32112605
[TBL] [Abstract][Full Text] [Related]
12. Identification of a Novel Quinoxaline-Isoselenourea Targeting the STAT3 Pathway as a Potential Melanoma Therapeutic.
Alcolea V; Karelia DN; Pandey MK; Plano D; Singh P; Palop JA; Amin S; Sanmartín C; Sharma AK
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691132
[TBL] [Abstract][Full Text] [Related]
13. Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
Yu W; Li C; Zhang W; Xia Y; Li S; Lin JY; Yu K; Liu M; Yang L; Luo J; Chen Y; Sun H; Kong L
J Med Chem; 2017 Apr; 60(7):2718-2731. PubMed ID: 28245116
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation.
Ashizawa T; Miyata H; Ishii H; Oshita C; Matsuno K; Masuda Y; Furuya T; Okawara T; Otsuka M; Ogo N; Asai A; Akiyama Y
Int J Oncol; 2011 May; 38(5):1245-52. PubMed ID: 21369699
[TBL] [Abstract][Full Text] [Related]
15. Targeting colon cancer with the novel STAT3 inhibitor bruceantinol.
Wei N; Li J; Fang C; Chang J; Xirou V; Syrigos NK; Marks BJ; Chu E; Schmitz JC
Oncogene; 2019 Mar; 38(10):1676-1687. PubMed ID: 30348989
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol suppresses cell proliferation via inhibition of STAT3 phosphorylation and Mcl-1 and cIAP-2 expression in HTLV-1-infected T cells.
Suzuki Y; Ito S; Sasaki R; Asahi M; Ishida Y
Leuk Res; 2013 Dec; 37(12):1674-9. PubMed ID: 24090995
[TBL] [Abstract][Full Text] [Related]
17. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo.
Huang W; Dong Z; Chen Y; Wang F; Wang CJ; Peng H; He Y; Hangoc G; Pollok K; Sandusky G; Fu XY; Broxmeyer HE; Zhang ZY; Liu JY; Zhang JT
Oncogene; 2016 Feb; 35(6):783-92. PubMed ID: 26073084
[TBL] [Abstract][Full Text] [Related]
18. LYR71, a derivative of trimeric resveratrol, inhibits tumorigenesis by blocking STAT3-mediated matrix metalloproteinase 9 expression.
Kim JE; Kim HS; Shin YJ; Lee CS; Won C; Lee SA; Lee JW; Kim Y; Kang JS; Ye SK; Chung MH
Exp Mol Med; 2008 Oct; 40(5):514-22. PubMed ID: 18985009
[TBL] [Abstract][Full Text] [Related]
19. Proteomic identification of the oncoprotein STAT3 as a target of a novel Skp1 inhibitor.
Cheng X; Liu YQ; Wang GZ; Yang LN; Lu YZ; Li XC; Zhou B; Qu LW; Wang XL; Cheng YX; Liu J; Tao SC; Zhou GB
Oncotarget; 2017 Jan; 8(2):2681-2693. PubMed ID: 27835873
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of STAT3 expression and signaling in resveratrol-differentiated medulloblastoma cells.
Yu LJ; Wu ML; Li H; Chen XY; Wang Q; Sun Y; Kong QY; Liu J
Neoplasia; 2008 Jul; 10(7):736-44. PubMed ID: 18592012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
